ALFA Filings
Every announcement, straight from the exchange
Every Sat Kartar Life earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Sat Kartar Life is pivoting from pure Ayurveda products to an integrated healthcare model, showing strong revenue growth but scaling back prior top-line guidance to prioritize margins.
H1 FY27 deck discloses no revenue, PAT or EBITDA figures. Balance sheet is debt-free with ₹18.7 Cr net cash. Growth is hospital-led: 30-bed Delhi unit at breakeven, 300 beds targeted by FY27-end.
Sat Kartar Life reported 23% revenue growth crossing ₹200cr in FY26. Transitioning from product-focused to an integrated Ayurvedic healthcare ecosystem including hospitals.
Sat Kartar Life transitioned from a product-focused entity to a healthcare ecosystem, delivering record growth in FY26. Management is aggressively targeting 150% revenue growth by FY28 through massive hospital bed expansion and US market entry.